Want to see VRCA full AI Analyst Report?
VRCA Stock Chart & Stats
$4.94
$0.31(6.08%)
At close: 4:00 PM EDT
$4.94
$0.31(6.08%)
Day’s Range― - ―
52-Week Range$3.28 - $9.82
Previous CloseN/A
Volume76.83K
Average Volume (3M)86.52K
Market Cap
$92.59M
Enterprise Value$121.00
Total Cash (Recent Filing)$11.20M
Total Debt (Recent Filing)$1.81M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 09, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding17,178,785
10 Day Avg. Volume157,161
30 Day Avg. Volume86,520
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.67Price Target Upside176.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$24.88M
Bulls Say, Bears Say
Bulls Say
YCANTH Commercial MomentumRising prescription volume and prescriber adoption indicate improving commercial traction for YCANTH. Sustained unit growth can expand the recurring product-revenue base and strengthen Verrica’s position in clinician-administered molluscum treatment.
Strong Product EconomicsYCANTH’s very high gross margin provides attractive contribution economics as volume scales. Although operating expenses remain elevated, durable product-level profitability gives management a stronger foundation to absorb commercial investment and pursue eventual operating leverage.
Funded Pipeline And International ExpansionExternal funding materially reduces Verrica’s share of near-term common-warts trial costs, while international distribution broadens potential commercialization. These partnerships preserve global rights in other regions and create multiple long-term growth avenues beyond YCANTH.
Bears Say
Persistent UnprofitabilityThe company has not converted strong gross margins into operating profitability because its revenue base remains insufficient to cover costs. Continued losses reduce financial flexibility and make future performance dependent on substantial revenue growth or expense reductions.
Cash Burn And Financing DependenceOngoing cash consumption means Verrica remains reliant on external capital until profitability improves. The contingent portion of its credit facility depends on achieving milestones, and the SOFR-plus-8% pricing with a 16% IRR catch-up increases the cost of extending runway.
Elevated Development And Commercial CostsInvestment in Phase III trials and commercial expansion may support future growth, but the current cost structure is expanding faster than the business can absorb. Unless these investments generate substantial revenue, they will prolong losses and increase funding requirements.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.28 and its highest was $9.82 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $92.59M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 66 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.232.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.5.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -5.224%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (176.65% Upside)
$13.67 (176.65% Upside)
Blogger Sentiment
Neutral
VRCA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $210.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.1%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of clear commercial momentum for YCANTH (robust unit growth, quarter-over-quarter revenue gains, new international distribution, and strong trial progress) and encouraging clinical signals (VP-315 Phase II abscopal effects and active Phase III enrollment for common warts). Offsetting these positives are sizable year-over-year revenue decline driven by last year’s one-time milestone, substantial GAAP and non-GAAP losses, materially higher R&D and SG&A expense, a legal settlement charge, and a relatively modest cash balance that makes the company reliant on a conditional credit facility. Management’s nondilutive financing and Torii’s substantial trial funding materially de-risk near-term liquidity and program funding, but financial outcomes remain contingent on milestone achievement, careful draw decisions, and successful trial readouts.View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
$13.67
▲(176.65% Upside)
Technical Analysis
Ownership Overview
47.73% Insiders
2.06% Mutual Funds
20.24% Other Institutional Investors
27.64% Public Companies and
Individual Investors